治疗肝移植术后乙肝复发的药物进展

乙肝复发是影响肝移植成功的重要因素, 未作预防者移植后HBV 的复发接近80 %, HBV 的再感染居乙肝肝硬化肝移植后死亡原因的首位。由于肝移植后乙肝复发HBV 的复制水平十分高且同时接受免疫抑制治疗及移植物疾病的迅速发展, HBV感染后的移植物治疗十分困难。目前临床正在不断摸索预防和治疗肝移植术后乙肝复发的药物治疗方案, 因此该类药物的开发和应用成为倍受关注的焦点。现用于预防和治疗HBV 再感染的药物主要可分为被动免疫(抗乙肝免疫球蛋白) 和抗病毒治疗药物(干扰素、核苷类似物抗病毒药物等) 。其中拉米夫定被认为是治疗HBV 感染最有前途的新药。本文旨在为临床提供治疗参考, 就以上药物的应用特点进行介绍。

Therapeutic progress on the treatment of hepatitis B recurrence after liver transplantation

Hepatitis B recurrence is an important factor to show whether liver transplantation is successful or not.Recrrrence rate is nearly 80 % in the patients liver transplantation, and HBV reinfection is the main cause of death.After the operation, HBV may copy very quickly, because of taking in immunosuppressant therapy and graft diseases develop rapidly.Recently, the exploitation and application of therapy has becomea focus.Now the drugs of preventing and treating HBV reinfection are mainly sortedinto passive immunity agents (Hepatitis B im-munoglobulin) andantivirus therapeutic agents(interferon and nucleotide analog antivirus drugs, etc)..Lamivudine is considered the most promising new drug of treating HBV infection.This article introduced the therapeutic characteristic of these drugs.